期刊文献+

Establishment of a high-throughput screening system for universal anti-HIV targets 被引量:3

Establishment of a high-throughput screening system for universal anti-HIV targets
原文传递
导出
摘要 The process of identifying novel human immunodeficiency virus 1 (HIV-1) inhibitors presents a challenge for industrial and scientific research.Virus-cell-based screening approaches offer some advantages in the quest for novel inhibitors because they include multiple targets in a single screen and in some cases reveal targets not captured in biochemical assays.In this study,a high-throughput screening (HTS) system for HIV-1 inhibitors was developed,which allows the simultaneous screening of all the HIV-1 targets required for replication in the cell culture.HeLa/cluster of differentiation 4 (CD4)/long terminal repeat (LTR) indicator cells,which stably expressed high levels of HIV receptor CD4 and contained the firefly luciferase reporter gene under the control of the HIV-1 LTR promoter,were generated.The expression of CD4 and LTR function in this cell line was validated by Western blot and luciferase assay.MT2 cells,a human T-cell leukemia cell line that support high levels of HIV-1 replication,were infected with HIV-1,and then the infected MT2 cells were co-cultured with HeLa/CD4/LTR cells.In the optimized assay conditions,HIV-1 replication occurs rapidly in the MT2 cells,resulting in the infection of the HeLa/CD4/LTR cells and a significant induction of luciferase signals through LTR,which is activated by the expression of HIV-1 tat gene.The luciferase signals of HeLa/CD4/LTR cells co-cultured with HIV-1 infected MT2 cells were significantly stronger than the signals of noninfected HeLa/CD4/LTR cells (P < 0.001).The inhibitory effects of HIV-1 inhibitors (3'-Azido-3'-deoxythymidine [AZT],efavirenz [EFV],and nevirapine [NVP]) were evaluated with this assay,and the inhibitory concentration 50% (IC50) values of the above three inhibitors were 58,1.4,and 85 nmol/L,respectively,indicating that the assay provides the necessary sensitivity for identifying antiviral molecules.The Z' factor had a value of 0.563,indicating this is a very robust assay.These results suggested that HIV-1 infection assay represents a novel approach to HIV-1 antiviral screening that allows for the effective execution of HTS campaigns. The process of identifying novel human immunodeficiency virus 1 (HIV-1) inhibitors presents a challenge for industrial and sci- entific research. Virus-cell-based screening approaches offer some advantages in the quest for novel inhibitors because they include multiple targets in a single screen and in some cases reveal targets not captured in biochemical assays. In this study, a high-throughput screening (HTS) system for HIV-1 inhibitors was developed, which allows the simultaneous screening of all the HIV-1 targets required for replication in the cell culture. HeLa/cluster of differentiation 4 (CD4)/long terminal repeat (LTR) indicator cells, which stably expressed high levels of HIV receptor CD4 and contained the firefly luciferase reporter gene under the control of the HIV-1 LTR promoter, were generated. The expression of CD4 and LTR function in this cell line was validated by Western blot and luciferase assay. MT2 cells, a human T-cell leukemia cell line that support high levels of HIV-1 replication, were infected with HIV-1, and then the infected MT2 cells were co-cultured with HeLa/CD4/LTR cells. In the optimized assay conditions, HIV-1 replication occurs rapidly in the MT2 cells, resulting in the infection of the HeLa/CD4/LTR cells and a significant induction of luciferase signals through LTR, which is activated by the expression of HIV-1 tat gene. The luciferase signals of HeLa/CD4/LTR cells co-cultured with HIV-1 infected MT2 cells were significantly stronger than the signals of noninfected HeLa/CD4/LTR cells (P 〈 0.001). The inhibitory effects of HIV-1 inhibitors (3'-Azido-3'-deoxythymidine [AZT], efavirenz [EFV], and nevirapine [NVP]) were evaluated with this assay, and the inhibitory concentration 50% (IC50) values of the above three inhibitors were 58, 1.4, and 85 nmol/L, respectively, indicating that the assay provides the necessary sensitivity for identifying antiviral molecules. The Z' factor had a value of 0.563, indicating this is a very robust assay. These results suggested that HIV-1 infection assay represents a novel approach to HIV-1 antiviral screening that allows for the effective execution of HTS campaigns.
出处 《Chinese Science Bulletin》 SCIE EI CAS 2010年第10期937-942,共6页
关键词 HIV-1 高产量的屏蔽 禁止者 virus-cell-based 试金 HIV-1, high-throughput screening, inhibitor, virus-cell-based assay
  • 相关文献

参考文献35

  • 1Hartzell J D, Janke I E, Weintrob A C. Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother, 2008, 62: 246-255.
  • 2Nasoodi A, Lim L T, Al-Ani A, et al. What you can see in your patient's eyes? Review of ocular manifestations of HIV in HAART era. Intl J STD AIDS, 2008, 19:4-11.
  • 3Aquaro S, Svicher V, Ronga L, et al. HIV-1-associated dementia during HAART therapy. Recent patents on CNS drug discovery, 2008, 3: 23-33.
  • 4Martins S, Ramos M J, Feruandes P A. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Meal Chem, 2008, 15:1083-1095.
  • 5Schurmann D, Wesselmann H, Kurowski M, et al. Kaletra single agent HAART after intolerance of NRTI- and NNRTI-containing regimens following kidney transplantation. Infection, 2007, 35: 194-196.
  • 6Bongiovanni M, Gianotti N, Chiesa E, et al. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Infection, 2007, 35:451-456.
  • 7Apuzzo L G, Vaida F, Gallant J E, et al. Tolerability and efficacy of P1 versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr, 2009 50:267-275.
  • 8Young J, Rickenbach M, Weber R, et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther, 2005, 10:73-81.
  • 9Shafer R W, Schapiro J M. HIV-1 drug resistance mutations: An up-dated framework for the second decade of HAART. AIDS Rev, 2008, 10:67-84.
  • 10Yeni P. Update on HAART in HIV. J Hepatol, 2006, 44:S100-S103.

同被引文献4

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部